Drugs / Keytruda
Keytruda cost
pembrolizumab · Merck. Every official price for Keytruda, side by side, with who pays it.
Short answer
Merck lists Keytruda at $12,517.44 per dose given every 3 weeks ($25,034.88 for a dose given every 6 weeks), as of September 2026. Medicare Part B pays up to $62.253 per mg for Keytruda, IV and $32.307 per mg for Keytruda Qlex, under the skin (October 1, 2026 to December 31, 2026). In 2024, Medicare Part B spent $6.0 billion on Keytruda (HCPCS J9271), an average of $13,136.81 per claim (CMS).126
Source: Merck and CMS · checked Nov 15, 2026
Keytruda: the official numbers, by situation
| Price | Amount | Whose price, and who it applies to | Date |
|---|---|---|---|
| List price per dose given every 3 weeks ($25,034.88 for a dose given every 6 weeks) | $12,517.441 | Merck's price to wholesalers (WAC). Most people don't pay it directly. | September 2026 |
| Medicare Part B payment limit per mg, Keytruda, IV | $62.2532 | What Medicare pays when the drug is paid under Part B (for example, given in a clinic). CMS lists Part B coinsurance for this code as 20%. | October 1, 2026 – December 31, 2026 |
| Medicare Part B payment limit per mg, Keytruda Qlex, under the skin | $32.3072 | What Medicare pays when the drug is paid under Part B (for example, given in a clinic). CMS lists Part B coinsurance for this code as 20%. | October 1, 2026 – December 31, 2026 |
None of these is your price at the counter: that depends on how you pay. Details and sources for each number are further down.
FDA approval
- Keytruda (pembrolizumab) was first approved by the FDA on Sep 4, 2014, under application BLA125514.4
Every official price
| Price | Amount | What it is | Date |
|---|---|---|---|
| Maker's list price (WAC) | $12,517.441 | Per dose given every 3 weeks ($25,034.88 for a dose given every 6 weeks). The price the maker charges wholesalers; most people do not pay it directly. | September 2026 (checked Oct 22, 2026) |
| Medicare Part B payment limit Keytruda, IV (pembrolizumab) · HCPCS J9271 | $62.2532 | Per 1 mg, when given in a clinic or hospital outpatient setting and paid under Part B. CMS lists Part B coinsurance for this code as 20%. | October 1, 2026 – December 31, 2026 |
| Medicare Part B payment limit Keytruda Qlex, under the skin (pembrolizumab and berahyaluronidase alfa) · HCPCS J9277 | $32.3072 | Per 1 mg, when given in a clinic or hospital outpatient setting and paid under Part B. CMS lists Part B coinsurance for this code as 20%. | October 1, 2026 – December 31, 2026 |
| Pharmacy acquisition cost (NADAC) | Not listed | This drug is not in the NADAC survey, which covers drugs dispensed by retail pharmacies. | — |
These are prices the drug company, Medicare and pharmacies use. What you pay depends on your coverage; see below. CMS notes that a code's presence in its payment file does not by itself mean Medicare covers the drug.3
What Medicare spent on Keytruda in 2024
CMS publishes what Part D spent on each drug each year. Its spending is the gross drug cost, which includes what Medicare, the plan and the patient paid,7 and it does not reflect manufacturers' rebates.8
Medicare Part D, calendar year 2024 (CMS Medicare Part D Spending by Drug, checked Nov 15, 2026).
| Product (as CMS lists it) | Total spending | Fills | People | Per fill | Per person |
|---|---|---|---|---|---|
| Keytruda | $140.1 million5 | 11,882 | 1,906 | $11,787.1610 | $73,481.1311 |
For doses given in a clinic and paid under Part B, CMS's spending is the full value of the drug, including the Medicare payment and what the patient owed.9
Medicare Part B, calendar year 2024 (CMS Medicare Part B Spending by Drug, checked Nov 15, 2026).
| HCPCS code | Total spending | Claims | People | Per claim | Per person |
|---|---|---|---|---|---|
| J9271 Injection, pembrolizumab, 1 mg | $6.0 billion6 | 455,858 | 75,361 | $13,136.81 | $79,464.46 |
These are totals and averages across everyone in Medicare who used the drug, not a price for one person. Averages per person depend on how long and how much each person used it.
With Medicare
- When given in a clinic and paid under Medicare Part B, Medicare's payment is based on the limit above, and CMS lists the coinsurance as 20%.2 A Medicare Supplement (Medigap) policy or Medicare Advantage plan changes what you pay.
- Higher income? Part B and Part D premiums can include IRMAA: IRMAA brackets.
With commercial insurance or no insurance
- What you pay depends on your plan's copay or coinsurance. The maker lists its savings and support options here: Merck: KEYTRUDA cost and financial help. We link to it but do not copy its terms.
Which drug, which dose, and whether to start, stop or switch are medical decisions. Ask your doctor or pharmacist.
Get an email when a price or rule changes
Only when an official GLP-1 self-pay price or a Medicare or Medicaid rule changes, at most once a week, with the official source for every change.
Official sources for this page (11)
“The list price for each indicated dose of KEYTRUDA when given every 3 weeks is $12,517.44. The list price for each indicated dose of KEYTRUDA when given every 6 weeks is $25,034.88. The list price is current as of September 2026.”
Merck: Keytruda pricing (entered by hand) · as of Oct 22, 2026- CMS: Medicare Part B Payment Limit File (quarterly ASP pricing) · as of Oct 23, 2026
“The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate whether Medicare covers a drug.”
CMS: Medicare Part B Payment Limit File (quarterly ASP pricing) · as of Oct 23, 2026“BLA125514 ORIG-1 approved 20140904”
FDA (Drugs@FDA via openFDA): BLA125514 · as of Nov 15, 2026“Keytruda: Tot_Spndng_2024 140055039.83, Tot_Clms_2024 11882, Tot_Benes_2024 1906”
CMS: Medicare Part D Spending by Drug, 2024 (data.cms.gov) · as of Nov 15, 2026“J9271 Injection, pembrolizumab, 1 mg: Tot_Spndng_2024 5988521233, Tot_Clms_2024 455858, Tot_Benes_2024 75361”
CMS: Medicare Part B Spending by Drug, 2024 (data.cms.gov), HCPCS J9271 · as of Nov 15, 2026“Drug spending metrics for Part D drugs are based on the gross drug cost, which represents total spending for the prescription claim, including Medicare, plan, and beneficiary payments.”
CMS: Medicare Part D Spending by Drug (about the data) · as of Nov 15, 2026“The Part D spending metrics do not reflect any manufacturers' rebates or other price concessions as CMS is prohibited from publicly disclosing such information.”
CMS: Medicare Part D Spending by Drug (about the data) · as of Nov 15, 2026“Drug spending metrics for Part B drugs represent the full value of the product, including the Medicare payment and beneficiary liability.”
CMS: Medicare Part B Spending by Drug (about the data) · as of Nov 15, 2026“Part D drug spending divided by the number of prescription fills.”
CMS: Medicare Part D Spending by Drug data dictionary · as of Nov 15, 2026“Total Part D drug spending divided by the number of unique beneficiaries utilizing the drug during the benefit year.”
CMS: Medicare Part D Spending by Drug data dictionary · as of Nov 15, 2026